Physician

Perry P Guaglianone, M.D.

According to 2025 Medicare claims, Perry Guaglianone, M.D. (NPI: 1932168309) practices hematology/oncology in the Decatur, IL market, with the plurality of this provider's patient population coming from Macon, IL. This provider's primary affiliated billing organization is CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS, S.C. (NPI: 1871580142; TIN: 371160364) and primary practice location at 62526-5858. Guaglianone is affiliated with the IRCCO (ACO ID: A2619), participating under the MSSP model.

Guaglianone's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 698 traditional Medicare patients, billed 238,067 HCPCS/CPT codes, and received $3,420,718 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,658 prescription claims across 316 beneficiaries totaling $4,610,892 in drug costs, led by Revlimid (Lenalidomide). DME data shows 13 claims. Open Payments data shows 167 records totaling $3,250. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,105,229 and ending at $3,420,718. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,414,423 to $4,610,892. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $19,329 to $952.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	600	179,128	$2,105,229
2016	576	145,862	$1,787,081
2017	656	207,956	$2,365,244
2018	638	156,876	$3,143,722
2019	630	226,110	$3,633,579
2020	482	165,846	$3,311,747
2021	509	164,043	$2,566,889
2022	558	149,320	$2,613,108
2023	535	155,973	$2,829,794
2024	698	238,067	$3,420,718

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	186	1,361	$1,414,423
2016	178	1,163	$2,213,933
2017	189	1,104	$2,177,145
2018	199	1,295	$2,120,363
2019	177	1,097	$2,200,439
2020	162	1,141	$2,619,058
2021	191	1,257	$2,959,695
2022	208	1,357	$3,546,979
2023	216	1,283	$4,313,891
2024	316	1,658	$4,610,892

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	164	$11,715
2016	N/R	38	$1,546
2017	N/R	N/R	N/R
2018	N/R	56	$5,402
2019	N/R	91	$6,071
2020	N/R	31	$1,986
2021	N/R	12	$1,392
2022	N/R	58	$2,330
2023	N/R	44	$5,828
2024	N/R	13	$659

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	521	1,537	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	481	981	$12
80053	Blood test, comprehensive group of blood chemicals	468	1,404	$10
36415	Insertion of needle into vein for collection of blood sample	442	1,303	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	330	705	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	54	1,512	$896,224
Jakafi	Ruxolitinib Phosphate	25	750	$431,047
Cabometyx	Cabozantinib S-Malate	15	450	$389,601
Imbruvica	Ibrutinib	22	616	$359,114
Abiraterone Acetate	Abiraterone Acetate	72	2,160	$272,386

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$659

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	167	$3,250	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Perry P. Guaglianone, M.D.?

Tedicare shows public-source Medicare data for Perry P. Guaglianone, M.D. (NPI 1932168309), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Perry P. Guaglianone, M.D. have ACO affiliation data?

Perry P. Guaglianone, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619).

What billing organization is linked to Perry P. Guaglianone, M.D.?

Perry P. Guaglianone, M.D. is linked to CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS, S.C. (billing NPI 1871580142) in the available physician profile data.

Does Perry P. Guaglianone, M.D. have Open Payments data?

Perry P. Guaglianone, M.D. has 167 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.